Latest Breaking News On - Zoe bolt - Page 2 : comparemela.com

Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoAndreas pahlSylvia wimmerHeidelberg pharmaKatie flintMary clarkDrug administrationFrankfurt stock exchangeHeidelberg pharma research gmbStrategic communicationsAmerican association for cancer researchMc servicesCorporate communicationsAntibody drug conjugatesOrphan drug designation

EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesSan diegoKatie flintMary clarkAndreas pahlHeidelberg pharmaSylvia wimmerCorporate communicationsHeidelberg pharma research gmbDrug administrationFrankfurt stock exchangeStrategic communicationsMc servicesAmerican association for cancer researchAntibody drug conjugatesOrphan drug designation

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMichaels weissSclerosis international federationHealthcare products regulatory agencyBriumvi european medicines agencyNational multiple sclerosis societyTrademark officeTg therapeutics incGlobe newswire tg therapeutics incExchange commissionEuropean commissionUnited states patentChief executive officerHepatitisb virusMultifocal leukoencephalopathy

Update on Regulatory Review of leriglitazone in the EU

Update on Regulatory Review of leriglitazone in the EU

Comunidad autonoma de catalunaUnited statesMarc martinellLaboratorios lesviMichelle boxallThomas dierksImage box communicationsStrategic communicationsNeuraxpharm pharmaceuticalsNeuraxpharm groupCommittee for medicinal products human useRoche venture fundMinoryx therapeuticsMedicinal productsHuman useHematopoietic stem cell transplantation

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

United kingdomSan franciscoUnited statesCharlotte hepburne scottStephen adamsHelena batesRegulatory agencyTheragnostics ltdStrategic communicationsUnited kingdom basedChief executive officerAriceum therapeuticsBiotech showcaseZoe bolt